Literature DB >> 11507210

Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

A Leen1, P Meij, I Redchenko, J Middeldorp, E Bloemena, A Rickinson, N Blake.   

Abstract

Human CD4(+) T-helper 1 cell responses to Epstein-Barr virus (EBV) infection are likely to be important in the maintenance of virus-specific CD8(+) memory and/or as antiviral effectors in their own right. The present work has used overlapping peptides as stimulators of gamma interferon release (i) to identify CD4(+) epitopes within four EBV latent-cycle proteins, i.e., the nuclear antigens EBNA1 and EBNA3C and the latent membrane proteins LMP1 and LMP2, and (ii) to determine the frequency and magnitude of memory responses to these proteins in healthy virus carriers. Responses to EBNA1 and EBNA3C epitopes were detected in the majority of donors, and in the case of EBNA1, their antigen specificity was confirmed by in vitro reactivation and cloning of CD4(+) T cells using protein-loaded dendritic cell stimulators. By contrast, responses to LMP1 and LMP2 epitopes were seen much less frequently. EBV latent-cycle proteins therefore display a marked hierarchy of immunodominance for CD4(+) T-helper 1 cells (EBNA1, EBNA3C >> LMP1, LMP2) which is different from that identified for the same proteins with respect to CD8(+)-T-cell responses (EBNA3C > EBNA1 > LMP2 >> LMP1). Furthermore, the range of CD4(+) memory T-cell frequencies in peripheral blood of healthy virus carriers was noticeably lower and narrower than the corresponding range of latent antigen-specific CD8(+)-T-cell frequencies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507210      PMCID: PMC115110          DOI: 10.1128/jvi.75.18.8649-8659.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.

Authors:  E Rajnavölgyi; N Nagy; B Thuresson; Z Dosztányi; A Simon; I Simon; R W Karr; I Ernberg; E Klein; K I Falk
Journal:  Int Immunol       Date:  2000-03       Impact factor: 4.823

3.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Direct immunosuppressive effects of EBV-encoded latent membrane protein 1.

Authors:  D F Dukers; P Meij; M B Vervoort; W Vos; R J Scheper; C J Meijer; E Bloemena; J M Middeldorp
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.

Authors:  K Bickham; C Münz; M L Tsang; M Larsson; J F Fonteneau; N Bhardwaj; R Steinman
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

6.  The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.

Authors:  N Blake; T Haigh; G Shaka'a; D Croom-Carter; A Rickinson
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  The cellular basis for viral-induced immunodeficiency: analysis by monoclonal antibodies.

Authors:  E L Reinherz; C O'Brien; P Rosenthal; S F Schlossman
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

8.  Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.

Authors:  J Dillner; L Sternås; B Kallin; H Alexander; B Ehlin-Henriksson; H Jörnvall; G Klein; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

9.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

10.  Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Authors:  C Münz; K L Bickham; M Subklewe; M L Tsang; A Chahroudi; M G Kurilla; D Zhang; M O'Donnell; R M Steinman
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  76 in total

1.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells.

Authors:  Ronald J C L M Vuylsteke; Paul A M van Leeuwen; Sybren Meijer; Pepijn G J T B Wijnands; Markwin G Statius Muller; Dirk H Busch; Rik J Scheper; Tanja D de Gruijl
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

3.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

4.  Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.

Authors:  Trygve Holmøy; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

Review 5.  Adoptive T-Cell Immunotherapy.

Authors:  Stephen Gottschalk; Cliona M Rooney
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.

Authors:  C W Tsang; X Lin; N H Gudgeon; G S Taylor; H Jia; E P Hui; A T C Chan; C K Lin; A B Rickinson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

8.  Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.

Authors:  Kevin N Heller; Jenica Upshaw; Beza Seyoum; Henry Zebroski; Christian Münz
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

Review 9.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

10.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.